In breast cancer, SNHG5 activates a metabolic reprogramming program by regulating BACH1 through miR-299, thereby upregulating glycolytic enzymes such as HK2 and PFK1, and promoting proliferation via enhanced aerobic glycolysis [43]. Here, PFKM is linked to breast carcinoma.